Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02959489 · ClinicalTrials.gov registry record · NA
Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)
A NA study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 315
- Enrollment target
NCT02959489 is a NA study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 315 participants.
The verdict
NCT02959489, a NA study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 315 participants
- Enrollment target
Study Summary
This study is intended to examine the impact of learning amyloid brain imaging results among asymptomatic older adults, and how to safely communicate these results and educate on the risk of developing Alzheimer's disease.
Interventions
- BEHAVIORAL Alzheimer's Disease Risk Disclosure
- BEHAVIORAL Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2016-11 |
| Est. Completion | 2021-04-29 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02959489
The ClinicalTrials.gov registry entry for NCT02959489 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 315 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Alzheimer's Disease Risk Disclosure is the first listed.
NCT02959489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02959489 about?
NCT02959489 is a clinical study titled "Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)". This study is intended to examine the impact of learning amyloid brain imaging results among asymptomatic older adults, and how to safely communicate these results and educate on the risk of developing Alzheimer's disease.
What is the current status of trial NCT02959489?
This trial is currently completed. It is a NA study. The enrollment target is 315 participants. The study started on 2016-11. Estimated completion is 2021-04-29.
What interventions are being tested in trial NCT02959489?
The interventions under investigation include: Alzheimer's Disease Risk Disclosure (BEHAVIORAL), Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure (BEHAVIORAL).
Who is sponsoring clinical trial NCT02959489?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.